{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:01:32Z","timestamp":1793908892891,"version":"4.8.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Patients with heart failure with preserved ejection fraction (HFpEF) who have left ventricular ejection fraction (LVEF) of 60% or greater have limited treatment options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with LVEF of 60% or greater.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The EMBARK-HFpEF trial was a phase 2a, open-label, single-arm, multicenter trial conducted from November 6, 2020, to February 26, 2024, at 20 sites in the US and Canada. Patients with symptomatic HFpEF (defined as a New York Heart Association [NYHA] functional class II or III), LVEF of 60% or greater, elevated N-terminal pro-B-type natriuretic peptide (NTproBNP), and left ventricular hypertrophy were eligible for inclusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Mavacamten treatment for 26 weeks, starting at 2.5 mg and potentially titrated up to 5 mg at week 14 based on prespecified LVEF and NTproBNP criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high-sensitivity troponin T (hsTnT); additional efficacy end points included changes in high-sensitivity troponin I (hsTnI), NYHA functional class, and echocardiographic parameters (resting and peak exercise). Safety end points included treatment-emergent adverse events and reductions in LVEF to less than 30%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 30 patients were enrolled and treated with mavacamten. Median (IQR) patient age was 76 (70-80) years, and 16 patients (53.3%) were female. From baseline to week 26, mavacamten was associated with reductions in NTproBNP (mean reduction, \u221226%; 95% CI, \u221244% to \u22124%; <jats:italic>P<\/jats:italic>\u2009=\u2009.04), hsTnT (mean reduction, \u221213%; 95% CI, \u221223% to \u22123%; <jats:italic>P<\/jats:italic>\u2009=\u2009.02), and hsTnI (mean reduction, \u221220%; 95% CI, \u221232% to \u22126%; <jats:italic>P<\/jats:italic>\u2009=\u2009.01). Cardiac biomarker values returned toward baseline levels 8 weeks after drug discontinuation. NYHA class improved in 10 of 24 patients (41.7%) who had evaluable NYHA class data at the end of treatment, and improvements in echocardiographic markers of LV diastolic function were observed. Mean LVEF decreased by 3.2 absolute percentage points (95% CI, 1.1-5.4; <jats:italic>P<\/jats:italic>\u2009=\u2009.005) during treatment. Mavacamten was interrupted in 3 patients (10% of the study population; 95% CI, 2.1%-26.5%) due to protocol prespecified criteria of LVEF less than 50% (n\u2009=\u20092) or a more than 20% relative decrease from baseline (n\u2009=\u20091; nadir LVEF, 58%), with LVEF recovery observed in all 3 patients. There were no deaths or instances of LVEF less than 30%; 1 patient had worsening heart failure deemed unrelated to the study drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04766892\">NCT04766892<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.3810","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:30:26Z","timestamp":1727706626000},"page":"170","source":"Crossref","is-referenced-by-count":38,"title":["Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction"],"prefix":"10.1001","volume":"10","author":[{"given":"Sanjiv J.","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Rigolli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Javidialsaadi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Khadra","sequence":"additional","affiliation":[{"name":"Chicago Medical Research, Hazel Crest, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Little","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Wever-Pinzon","sequence":"additional","affiliation":[{"name":"University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali Tiku","family":"Owens","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Skali","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"hbr240015r1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hbr240015r2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?","volume":"41","author":"Wehner","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"hbr240015r3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.122.062022","article-title":"Delivering therapeutic efficacy across the ejection fraction spectrum of heart failure.","volume":"146","author":"Lam","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"hbr240015r4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ejhf.2895","article-title":"Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: insight from the JROADHF study.","volume":"25","author":"Horiuchi","year":"2023","journal-title":"Eur J Heart Failure"},{"issue":"5","key":"hbr240015r5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ejhf.2843","article-title":"Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction.","volume":"25","author":"Popovic","year":"2023","journal-title":"Eur J Heart Failure"},{"issue":"7","key":"hbr240015r6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.122.059280","article-title":"Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction.","volume":"146","author":"Rosch","year":"2022","journal-title":"Circulation"},{"issue":"44","key":"hbr240015r7","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"hbr240015r8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.120.051330","article-title":"Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: mavacamten in perspective.","volume":"143","author":"Maron","year":"2021","journal-title":"Circulation"},{"issue":"10253","key":"hbr240015r9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"hbr240015r10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy.","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hbr240015r11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","article-title":"Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.","volume":"63","author":"Kraigher-Krainer","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hbr240015r12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cardfail.2010.11.004","article-title":"Decreased cardiac functional reserve in heart failure with preserved systolic function.","volume":"17","author":"Norman","year":"2011","journal-title":"J Cardiac Failure"},{"issue":"9","key":"hbr240015r13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter.","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"hbr240015r14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40256-022-00532-x","article-title":"The Impact of mavacamten on the pathophysiology of hypertrophic cardiomyopathy: a narrative review.","volume":"22","author":"Edelberg","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"hbr240015r15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","article-title":"B-Type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.","volume":"47","author":"Iwanaga","year":"2006","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2824338\/jamacardiology_shah_2024_br_240015_1738111909.05043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T16:02:04Z","timestamp":1739376124000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2824338"}},"subtitle":["Primary Results of the EMBARK-HFpEF Trial"],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.3810","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}